Suscribirse

The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation - 17/06/21

Doi : 10.1016/j.biopha.2021.111767 
Jing Ming a, b , Weiyi Liu a , Hongwei Wu c , Yujin Li a, d , Erpeng Yang a, d , Ziqing Wang a, e , Haiyan Xiao a , Richeng Quan a, , Xiaomei Hu a,
a Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China 
b Postdoctoral Research Programme of China Academy of Chinese Medical Sciences, Beijing 100700, China 
c Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing100700, China 
d Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China 
e Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 18
Iconografías 12
Vídeos 0
Otros 0

Abstract

Background

Polycythemia vera (PV) is a refractory hematological disease that lack of effective therapy. Chinese traditional medicine Longchai Jiangxue formula (LCJX) has showed the powerful effects on PV. However, the active ingredients and mechanisms of this formula have not been elucidated. We explored the active ingredients and mechanisms of LCJX for treating PV.

Methods

The chemical constituents of LCJX were qualitatively analyzed by UPLC/Q-TOF-MS/MS. On this basis, the TCMSP, ETCM, PubChem BioAssay and ChEMBL databases were searched to predict the potential targets of chemical components of LCJX. Then Genecards, GEO, DisGeNET, and OMIM databases were used to retrieve data of targets related to PV. Drug-disease-target network and protein-protein-interaction (PPI) network were built. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed. Finally, Molecular docking, CCK-8 assay, Annexin V-FITC/PI staining and western blot were processed so as to screen the active components related to PV and elucidate its mechanisms.

Results

A total of 84 compounds were identified from LCJX by UPLC/Q-TOF-MS/MS. After removed duplicate items, there were 143 targets linked to both disease and drugs. Crucial genes, such as MTOR, HIF1A, JAK2, VEGFA, STAT3, AKT1, TERT, MAPK1, were shown in PPI network. GO enrichment indicated that oxidative stress process, tyrosine kinase activity and phosphatase binding function, and cell membrane structure were in reference to LCJX against PV. KEGG enrichment showed that JAK-STAT signaling pathway and PI3K-Akt signaling pathway, were put in an important position of the treatment. Furthermore, Molecular docking, CCK-8 assay, Annexin V-FITC/PI staining and western blot technique proved the therapeutic effect of Saikosaponin A, main ingredient of LCJX.

Conclusion

This study, combined with UPLC/Q-TOF-MS/MS, network pharmacology and molecular biology, provides a reference for the identification of effective components, screening of quality markers and analysis of its action mechanism of LCJX.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




ga1

El texto completo de este artículo está disponible en PDF.

Highlights

Traditional Chinese medicine “LongChaiJiangXue” is effective to Polycythemia Vera.
The UPLC technology is useful for biochemical analysis for medicine scientifically.
System pharmacology helps screen the main ingredients and mechanisms of the drugs.
Hub-genes and pathways were confirmed in vitro and in silico experimentally.
Molecular docking, cell viability assay and Western-blot experiment were processed.

El texto completo de este artículo está disponible en PDF.

Abbreviations : LCJX, PV, TCMSP, PPI, GO, KEGG, STAT-3, IL-6, JAK2, VEGFA, MPN, AML, GRR, RB, AMK, IN, RPR, RRR, TCM, OB, DL, PDB, BP, MF, CC, SSA

Keywords : Longchai Jiangxue formula, UPLC/Q-TOF-MS/MS, Network pharmacology, Active ingredient, Polycythemia vera


Esquema


© 2021  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 140

Artículo 111767- août 2021 Regresar al número
Artículo precedente Artículo precedente
  • Network pharmacology identifies IL6 as an important hub and target of tibolone for drug repurposing in traumatic brain injury
  • Andrew J. McGovern, George E. Barreto
| Artículo siguiente Artículo siguiente
  • Metformin has no impact on nitric oxide production in patients with pre-diabetes
  • Edyta Sutkowska, Paulina Fortuna, Bernadetta Ka?u?a, Karolina Sutkowska, Jerzy Wi?niewski, Andrzej Gamian Prof

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.